Further, CRC patients who had positive co-expression of IGF1 and HOXA13 exhibited the lowest overall survival and highest recurrence rates in both CRC cohorts (Fig. 3J, lower panel). This evidence concerns the gene IGF1 and colorectal carcinoma.